Publications:206
Video Visit Available
Accepting New Patients
Mount Sinai DoctorsTreats Children & Adults
Accepting New PatientsJohn E Levine, MD
Pediatrics, Pediatric Hematology-Oncology
No Patient Experience Ratings
Book an Appointment
About Me
John Levine, MD, MS is the Co-Director of the Mount Sinai Acute GVHD International Consortium (MAGIC) and Director of BMT Clinical Research at the Tisch Cancer Institute and a Professor of Internal Medicine and Pediatrics at the Icahn School of Medicine at Mount Sinai. His research program focused on allogeneic hematopoietic cell transplantation with an emphasis on improving outcomes for patients with graft-versus-host disease (GVHD). The centerpiece of Dr. Levine’s research is the MAGIC program, a collaborative effort among over 20 centers in North America, Europe, and Asia, that prospectively studies adult and pediatric recipients of an allogeneic HCT and contains the world’s largest data collection and biorepository dedicated to understanding the biology and clinical course of GVHD. Dr. Levine led the MAGIC effort that created the new international standard for clinical GVHD staging and grading and together with his laboratory collaborator, Dr. James Ferrara, they invented a biomarker blood test that accurately predicts outcomes for patients who require treatment for GVHD. This work has since been translated into clinical trials that test risk-adapted treatments to improve responses and decrease toxicity of GVHD therapy. In addition to his own research program, Dr. Levine has provided leadership to the field as the Chair of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) from 2024-2025 and the Chair of the Cellular Therapy Committee for Children’s Oncology Group (2016-2023).
Language
Position
Hospital Affiliations
- Mount Sinai Queens
- The Mount Sinai Hospital
Research Topics
Translational Research, Transplantation
About Me
John Levine, MD, MS is the Co-Director of the Mount Sinai Acute GVHD International Consortium (MAGIC) and Director of BMT Clinical Research at the Tisch Cancer Institute and a Professor of Internal Medicine and Pediatrics at the Icahn School of Medicine at Mount Sinai. His research program focused on allogeneic hematopoietic cell transplantation with an emphasis on improving outcomes for patients with graft-versus-host disease (GVHD). The centerpiece of Dr. Levine’s research is the MAGIC program, a collaborative effort among over 20 centers in North America, Europe, and Asia, that prospectively studies adult and pediatric recipients of an allogeneic HCT and contains the world’s largest data collection and biorepository dedicated to understanding the biology and clinical course of GVHD. Dr. Levine led the MAGIC effort that created the new international standard for clinical GVHD staging and grading and together with his laboratory collaborator, Dr. James Ferrara, they invented a biomarker blood test that accurately predicts outcomes for patients who require treatment for GVHD. This work has since been translated into clinical trials that test risk-adapted treatments to improve responses and decrease toxicity of GVHD therapy. In addition to his own research program, Dr. Levine has provided leadership to the field as the Chair of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) from 2024-2025 and the Chair of the Cellular Therapy Committee for Children’s Oncology Group (2016-2023).
Language
Position
Hospital Affiliations
- Mount Sinai Queens
- The Mount Sinai Hospital
Research Topics
Translational Research, Transplantation
Clinical Focus
- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia
- Adult Non-Hodgkin's Lymphoma
- Bone Marrow Transplantation
- Hematologic Malignancies
- Hematologic Malignancies, Pediatric
Education
MD, Eastern Virginia Medical School
Residency, Pediatrics
Children's Hospital-Los Angeles
Residency, Pediatrics
Children's Hospital of Los Angeles
Fellowship, Pediatric Hematology-Oncology
Memorial Sloan-Kettering Cancer Center
Fellowship, Pediatric Hematology-Oncology
Memorial Sloan-Kettering Cancer Center
Fellowship, Pediatric Blood & Marrow Transplant
Memorial Sloan-Kettering Cancer Center
Certifications
American Board of Pediatrics
Awards
2013
Chair, Pediatric Scientific Interest Group, ASBMT Annual Meeting
2012
Chair, Scientific Program, ASBMT Annual Meeting
2007
Best Doctors in America
2005
Ford Motor Company Leadership in Health Award
Research
My research focuses on clinical bone marrow transplantation. My primary research focus concentrates on clinical and translational studies for the diagnosis, prevention, and treatment of acute graft-versus-host disease (GVHD). In collaboration with the laboratory of James Ferrara, we developed and validated a GVHD plasma biomarker based scoring system that assigns patients to GVHD risk strata and can be used to determine treatment intensity.
Locations
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
Patients with Cigna Medicare Advantage or Humana Medicare Advantage insurance: Please read this important message before booking to find out if out-of-network costs may apply to your next visit.
- Ruttenberg Treatment Center1470 Madison Avenue, 3rd Floor, New York, NY, 10029
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
- Reparative immunological consequences of stem cell transplantation as a cellular therapy for refractory Crohn's disease. Daniela Guisado, Sayali Talware, Xiaoli Wang, Andrew Davis, Elbek Fozilov, Aaron Etra, Jean Frederic Colombel, Christoph Schaniel, Christopher Tastad, John E. Levine, James L.M. Ferrara, Chuang Ling-Shiang, Ksenija Sabic, Shishir Singh, Bridget K. Marcellino, Ronald Hoffman, Judy Cho, Louis Cohen. Gut
- Correction to: Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002 (Bone Marrow Transplantation, (2023), 58, 12, (1416-1418), 10.1038/s41409-023-02110-4). Gabrielle Meyers, Mehdi Hamadani, Michael Martens, Haris Ali, Patrice Chevallier, Hannah Choe, Andrew C. Harris, Ernst Holler, Eric van Hooren, Willem Klaassen, Eric Leifer, Ypke van Oosterhout, Lia Perez, Iskra Pusic, Matthias Stelljes, Walter van der Velden, Emanuele Ammatuna, David Beauvais, Jérôme Cornillon, Richard T. Maziarz, Johannes Schetelig, Jennifer Romeril, Margaret L. MacMillan, John E. Levine, Gérard Socié. Bone Marrow Transplantation
- Prediction and Prognostication of Acute Graft-Versus-Host Disease by MAGIC Biomarkers. John E. Levine. American Journal of Hematology
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Levine during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Equillium, Inc. HQ
- Incyte Corporation
- Bluebird Bio
- Beijing Yuanxin Wujie Management Consulting
- VectivBio AG
- Calliditas Therapeutics AB
- Glaxosmithkline
- Mesoblast Inc
- Medexus
- Kitch Attorneys and Counselors
- X4 Pharmaceuticals
- Forte Biosciences
- Symbio
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Levine during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Equillium, Inc. HQ
- Incyte Corporation
- Bluebird Bio
- Beijing Yuanxin Wujie Management Consulting
- VectivBio AG
- Calliditas Therapeutics AB
- Glaxosmithkline
- Mesoblast Inc
- Medexus
- Kitch Attorneys and Counselors
- X4 Pharmaceuticals
- Forte Biosciences
- Symbio
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.